The device was not returned for evaluation.A review of the lot history record identified no manufacturing nonconformities issued to the reported lot that would have contributed to this event.The reported patient effects of thrombosis and respiratory failure are listed in the xience pro a everolimus eluting coronary stent systems instructions for use as known patient effects of coronary stenting procedures.A conclusive cause for the reported patient effects, and the relationship to the product, if any, cannot be determined.There is no indication of a product quality issue with respect to manufacture, design or labeling.The xience proa device is currently not commercially available in the u.S.; however, it is similar to a device sold in the u.S.
|
It was reported that the procedure was performed to treat a lesion in the right coronary artery.The patient presented with a st-elevated myocardial infarction and cardiogenic shock on (b)(6) 2020.A 2.75x33mm and 3.5x28mm xience pro a stents were implanted.On (b)(6) 2020, in-stent thrombosis was noted in the middle segment of the 3.5x28mm xience pro a stent, and the patient experienced respiratory failure.An unspecified 3.75x20mm nc balloon and an unspecified 4x18mm xience stent were used as treatment.There was no clinically significant delay in the procedure.No additional information was provided.
|